|
MDA’s Search for Treatments & Cures
Since 1986, when MDA-funded researchers identified the gene that, when flawed, leads to DMD and BMD, scientists have built on that foundation to better understand the diseases. As of 2007, MDA investigators are pursuing several directions in search of a way to halt or reverse the muscle destruction of these disorders.
MDA-supported researchers have created a working dystrophin gene without the DMD mutation, and they’re now testing its safety in a small clinical trial in boys with the disease.
In another approach, MDA-supported researchers at a biotechnology company are testing PTC124, a drug that changes the way muscle cells “read” genetic instructions, in boys with DMD. In some 15 percent of boys with the disease, a molecular stop signal occurs too early in the DNA instructions for a complete dystrophin protein to be made. It’s this signal that PTC124 coaxes cells to ignore.
| MDA's Web site is constantly updated with the latest information about the neuromuscular diseases in its program. See the latest research news. |
Other MDA-backed scientists are experimenting with antisense oligonucleotides, compounds designed to encourage cells to skip over any type of genetic error, not just a stop signal. These compounds are undergoing laboratory testing, and a pilot clinical trial in the Netherlands has shown promising results.
Still other teams of MDA scientists are using stem cells isolated from muscle, blood vessels or bone marrow to regenerate muscles in laboratory models of DMD.
In addition, some groups are testing strategies to increase production of the protein utrophin, which closely resembles dystrophin but is produced normally in people with DMD or BMD. Laboratory evidence shows that increasing utrophin levels can to some extent compensate for a dystrophin deficiency.
|